-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Biopharmaceutical companies AbbVie and Genmab today announced updated results from a Phase I/II trial evaluating the bispecific antibody epcoritamab in patients with relapsed/refractory large B-cell lymphoma (LBCL).
Lymphoma CAR-T
The EPCORE NHL-1 trial is designed to evaluate epcoritamab in patients with relapsed, advanced or refractory CD20 + mature B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL)
+ Nearly 40% of whom received prior CAR-T cell therapy Nearly 40% of whom received prior CAR-T cell therapy AbbVie and Genmab said the ORR for this cohort was 63.
The most common grade 3 or 4 treatment-related adverse events included neutropenia, anemia, and thrombocytopenia
When the two companies formed a partnership in 2020 to develop next-generation bispecific antibodies, including epcoritamab, AbbVie paid Genmab $750 million upfront
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5549767 https://firstwordpharma.
com/story/5549767
Leave a comment here